Aurinia Pharmaceuticals (AUPH) Data Continues to Filter Out Bearish Concerns - Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St stocks end higher with major corporate earnings in view
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Cadence (CDNS) tumbles despite Q1 beat on top and bottom lines
- Tesla expands price cuts to China, Germany after reducing FSD cost; shares down
- Gold prices slide as M.East fears ease, rate jitters persist
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
FBR Reiterates Bullish View on Aurinia (AUPH) as Data Supports Strong Potential in Lupus Nephritis
October 6, 2016 1:18 PM EDTFBR Capital analyst Vernon Bernardino reiterated an Outperform rating and $9 price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) after the company announced positive updated results from its AURION open-label exploratory clinical study with twice-daily (BID) 23.7mg of voclosporin (VCS) in combination with mycophenolate mofetil and... More
Aurinia (AUPH) Says Open-Label AURION Data Shows Increased Remission Rates
October 6, 2016 8:09 AM EDTAurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (Aurinia or the Company) a clinical stage biopharmaceutical company focused on the global immunology market, today announced 24-week data in all 10 patients from the AURION study, an open-label exploratory study to assess the short-term predictors of response using voclosporin... More
Aurinia Pharmaceuticals (AUPH): Reiterating $10 PT After The Recent 33% Move - HC Wainwright
October 5, 2016 7:49 AM EDTH.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) after attending a KOL presentation hosted by the company. The presentation offered a thorough overview of lupus nephritis (LN), including historical mortality rates and current standard of care... More
Aurinia Pharmaceuticals (AUPH) Climbs to Session High, Up 9%
October 4, 2016 11:30 AM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) Climbs to Session High, Up 9%
... More
